Coronavirus: Vaccination

(asked on 29th November 2021) - View Source

Question to the Department of Health and Social Care:

To ask Her Majesty's Government what plans they have to monitor (1) immunocompromised patients' antibody levels, and (2) their variation over time, in response to the rollout of the third primary dose vaccination.


Answered by
Lord Kamall Portrait
Lord Kamall
This question was answered on 16th December 2021

The UK Health Security Agency (UKHSA) is monitoring the effectiveness of COVID-19 vaccinations in clinical risk groups, including those with immunosuppression. The VirusWatch study monitors antibody response over time following COVID-19 vaccination, including the third primary dose, among individuals with immunosuppression.

As part of the COVID-19 Immunity National Core Study, the UK Research and Innovation OCTAVE study is examining the immune response to COVID-19 vaccines in clinically at-risk groups. This includes vaccine responses in patients with certain immunosuppressed conditions. These analyses will monitor the duration of immunity from COVID-19 vaccination.

Reticulating Splines